MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

Search

Guardant Health Inc

Closed

SectorHealthcare

67.33 4.94

Overview

Share price change

24h

Current

Min

63.93

Max

68.19

Key metrics

By Trading Economics

Income

-4.7M

-100M

Sales

29M

232M

Profit margin

-43.044

Employees

1,999

EBITDA

22M

-89M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+8.65% upside

Dividends

By Dow Jones

Next Earnings

29 Oct 2025

Market Stats

By TradingEconomics

Market Cap

2.2B

7.7B

Previous open

62.39

Previous close

67.33

News Sentiment

By Acuity

50%

50%

170 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Guardant Health Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Oct 2025, 21:10 UTC

Major Market Movers

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 Oct 2025, 19:03 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 Oct 2025, 17:58 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 Oct 2025, 17:12 UTC

Earnings

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 Oct 2025, 17:12 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 Oct 2025, 16:59 UTC

Acquisitions, Mergers, Takeovers

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 Oct 2025, 23:44 UTC

Market Talk

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 Oct 2025, 23:42 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 Oct 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Oct 2025, 22:15 UTC

Earnings

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 Oct 2025, 22:15 UTC

Earnings

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 Oct 2025, 22:15 UTC

Earnings

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 Oct 2025, 22:02 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Oct 2025, 22:02 UTC

Market Talk

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 Oct 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 Oct 2025, 20:50 UTC

Market Talk
Earnings

Health Care Roundup: Market Talk

16 Oct 2025, 20:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Oct 2025, 20:23 UTC

Market Talk

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 Oct 2025, 20:20 UTC

Earnings

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 Oct 2025, 20:08 UTC

Acquisitions, Mergers, Takeovers

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 Oct 2025, 19:37 UTC

Acquisitions, Mergers, Takeovers

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 Oct 2025, 19:26 UTC

Earnings

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 Oct 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 Oct 2025, 19:23 UTC

Market Talk

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 Oct 2025, 19:23 UTC

Earnings

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 Oct 2025, 18:35 UTC

Market Talk
Earnings

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 Oct 2025, 18:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Oct 2025, 18:31 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Oct 2025, 18:31 UTC

Market Talk

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 Oct 2025, 16:57 UTC

Market Talk

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

8.65% upside

12 Months Forecast

Average 69.74 USD  8.65%

High 80 USD

Low 60 USD

Based on 21 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

21

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

38.86 / 47.41Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

170 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat